Surgical Outcomes in Benign Gynecologic Surgery Patients during the COVID-19 Pandemic (SOCOVID study).


Journal

Journal of minimally invasive gynecology
ISSN: 1553-4669
Titre abrégé: J Minim Invasive Gynecol
Pays: United States
ID NLM: 101235322

Informations de publication

Date de publication:
02 2022
Historique:
received: 15 07 2021
revised: 05 08 2021
accepted: 14 08 2021
pubmed: 27 8 2021
medline: 16 2 2022
entrez: 26 8 2021
Statut: ppublish

Résumé

To determine the incidence of perioperative coronavirus disease (COVID-19) in women undergoing benign gynecologic surgery and to evaluate perioperative complication rates in patients with active, previous, or no previous severe acute respiratory syndrome coronavirus 2 infection. A multicenter prospective cohort study. Ten institutions in the United States. Patients aged >18 years who underwent benign gynecologic surgery from July 1, 2020, to December 31, 2020, were included. All patients were followed up from the time of surgery to 10 weeks postoperatively. Those with intrauterine pregnancy or known gynecologic malignancy were excluded. Benign gynecologic surgery. The primary outcome was the incidence of perioperative COVID-19 infections, which was stratified as (1) previous COVID-19 infection, (2) preoperative COVID-19 infection, and (3) postoperative COVID-19 infection. Secondary outcomes included adverse events and mortality after surgery and predictors for postoperative COVID-19 infection. If surgery was delayed because of the COVID-19 pandemic, the reason for postponement and any subsequent adverse event was recorded. Of 3423 patients included for final analysis, 189 (5.5%) postponed their gynecologic surgery during the pandemic. Forty-three patients (1.3% of total cases) had a history of COVID-19. The majority (182, 96.3%) had no sequelae attributed to surgical postponement. After hospital discharge to 10 weeks postoperatively, 39 patients (1.1%) became infected with severe acute respiratory syndrome coronavirus 2. The mean duration of time between hospital discharge and the follow-up positive COVID-19 test was 22.1 ± 12.3 days (range, 4-50 days). Eleven (31.4% of postoperative COVID-19 infections, 0.3% of total cases) of the newly diagnosed COVID-19 infections occurred within 14 days of hospital discharge. On multivariable logistic regression, living in the Southwest (adjusted odds ratio, 6.8) and single-unit increase in age-adjusted Charlson comorbidity index (adjusted odds ratio, 1.2) increased the odds of postoperative COVID-19 infection. Perioperative complications were not significantly higher in patients with a history of positive COVID-19 than those without a history of COVID-19, although the mean duration of time between previous COVID-19 diagnosis and surgery was 97 days (14 weeks). In this large multicenter prospective cohort study of benign gynecologic surgeries, only 1.1% of patients developed a postoperative COVID-19 infection, with 0.3% of infection in the immediate 14 days after surgery. The incidence of postoperative complications was not different in those with and without previous COVID-19 infections.

Identifiants

pubmed: 34438045
pii: S1553-4650(21)00390-3
doi: 10.1016/j.jmig.2021.08.011
pmc: PMC8381624
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

274-283.e1

Informations de copyright

Copyright © 2021 AAGL. Published by Elsevier Inc. All rights reserved.

Auteurs

Rosanne M Kho (RM)

Women's Health Institute, Cleveland Clinic, Cleveland, Ohio (Drs. Kho and Chang).

Olivia H Chang (OH)

Women's Health Institute, Cleveland Clinic, Cleveland, Ohio (Drs. Kho and Chang). Electronic address: OliviaChangMD@gmail.com.

Adam Hare (A)

University of Texas Southwestern Medical Center, Dallas, Texas (Drs. Hare and Schaffer).

Joseph Schaffer (J)

University of Texas Southwestern Medical Center, Dallas, Texas (Drs. Hare and Schaffer).

Jen Hamner (J)

Indiana University Hospital, Indianapolis, Indiana (Drs. Hamner and Heit).

Gina M Northington (GM)

Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia (Drs. Northington and Metcalfe).

Nina Durchfort Metcalfe (ND)

Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia (Drs. Northington and Metcalfe).

Cheryl B Iglesia (CB)

Division of Urogynecology, Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, District of Columbia (Drs. Iglesia and Zelivianskaia).

Anna S Zelivianskaia (AS)

Division of Urogynecology, Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, District of Columbia (Drs. Iglesia and Zelivianskaia).

Hye-Chun Hur (HC)

Columbia University Irving Medical Center, New York, New York (Drs. Hur and Seaman).

Sierra Seaman (S)

Columbia University Irving Medical Center, New York, New York (Drs. Hur and Seaman).

Margaret G Mueller (MG)

Northwestern Memorial Hospital, Chicago, Illinois (Drs. Mueller and Milad).

Magdy Milad (M)

Northwestern Memorial Hospital, Chicago, Illinois (Drs. Mueller and Milad).

Charles Ascher-Walsh (C)

Mount Sinai Hospital, New York, New York (Drs. Ascher-Walsh and Kossl).

Kelsey Kossl (K)

Mount Sinai Hospital, New York, New York (Drs. Ascher-Walsh and Kossl).

Charles Rardin (C)

Women & Infants Hospital of Rhode Island, Providence, Rhode Island (Drs. Rardin and Siddique).

Moiuri Siddique (M)

Women & Infants Hospital of Rhode Island, Providence, Rhode Island (Drs. Rardin and Siddique).

Miles Murphy (M)

The Institute for Female Pelvic Medicine, Montgomeryville, Pennsylvania (Dr. Murphy).

Michael Heit (M)

Indiana University Hospital, Indianapolis, Indiana (Drs. Hamner and Heit).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH